Sulfadimethoxine sodium

Synonyms: Sulphadimethoxine sodium
Sulfadimethoxine (Sulphadimethoxine) sodium 是一种口服有效的磺胺类抗生素,可降低由 Eimeria 引起的死亡、体重下降和组织损伤,并可用于禽球虫病的相关研究。
产品编号: MS-L44709 纯度: 99.44% CAS No.: 1037-50-9 分子式: C12H13N4NaO4S 分子量: 332.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Sulfadimethoxine (Sulphadimethoxine) sodium 是一种口服有效的磺胺类抗生素,可降低由 Eimeria 引起的死亡、体重下降和组织损伤,并可用于禽球虫病的相关研究。

生物实验数据

生物活性 Sulfadimethoxine (Sulphadimethoxine) sodium is an orally effective sulfonamide antibiotic that reduces mortality, weight loss, and tissue damage caused by Eimeria and can be used in research related to avian coccidiosis.
IC50 & Target

Antibacterial

体外研究
(In Vitro)

Sulfadimethoxine (50 µg/mL;24 小时) sodium 在 37°C 条件下通过平衡透析法检测时,与家养短毛猫血浆蛋白的结合率高达 87.5%。

体内研究
(In Vivo)

Sulfadimethoxine (0.025-0.1%;口服给药;每日,连续 6 天) sodium 于感染后第 3 天开始给药,可完全保护 Eimeria tenella 感染雏鸡免于死亡,并减轻其病理损伤,其中 0.05%浓度组的雏鸡体重增幅最高。
Sulfadimethoxine (0.025-0.1%;口服给药;每日,连续 6 天) sodium 可对感染 Eimeria necatrix 的雏鸡提供完全的死亡保护并减轻病理损伤,而 0.025%的浓度对该虫种无效。
Sulfadimethoxine (0.025-0.1%;口服给药;每日,连续 6 天) sodium 可完全保护感染 Eimeria acervulina 的雏鸡免于死亡,并减轻其病理损伤;其中 0.05%剂量组的雏鸡体重增长水平与未感染对照组相当。
Sulfadimethoxine (0.025-0.1%;口服给药;每日,连续 6 天) sodium 可对感染 Eimeria maxima 的雏鸡提供完全的死亡保护,并减轻病理损伤,且所有剂量均能维持相近的体重增长。
Sulfadimethoxine (0.025-0.1%;口服给药;每日,连续 6 天) sodium 可对感染 Eimeria brunetti 的雏鸡提供完全的死亡保护,并消除其病理损伤。
Sulfadimethoxine (0.025-0.1%;口服给药;每日,连续 6 天) sodium 可完全保护感染 Eimeria mivati 的雏鸡免于死亡,并减轻其病理性损伤;其中 0.05%剂量组的雏鸡体重增长高于未感染对照组。
Sulfadimethoxine (0.05%;口服给药;每日,连续 6 天) sodium 可对混合 Eimeria 感染的雏鸡提供完全的死亡保护,并减轻其病理损伤。
Sulfadimethoxine (0.0125-0.1%;口服给药;每日,连续 6 天) sodium 于感染后第 3 天开始通过饮水给药,可完全保护感染 Eimeria gallopavonis 的火鸡雏鸡免于死亡,并减轻其病理损伤;其中 0.025%剂量组的体重增长优于未感染对照组。
Sulfadimethoxine (0.0125-0.1%;口服给药;每日,连续 6 天) sodium 可对感染 Eimeria meleagrimitis 的火鸡雏鸡提供完全的死亡保护,并减轻其病理损伤。
Sulfadimethoxine (0.0125-0.1%;口服给药;每日,连续 6 天) sodium 于感染后第 3 天开始通过饮水给药,可完全保护感染 Eimeria adenoeides 的雏火鸡免于死亡,并减轻其病理损伤。

Animal Model: Peterson Cross (1 day old, grouped by weight and sex, 2 weeks old at test initiation)
Dosage: 0.025%; 0.05%; 0.1%
Administration: p.o.; daily; 6 days
Result: Achieved 0% mortality, 82% weight gain relative to uninfected unmedicated controls (UUC), and average degree of infection (ADI) of 0.3 at 0.1% dose in Eimeria tenella-infected chicks.
Achieved 0% mortality, 89% weight gain relative to UUC, and ADI of 0.8 at 0.05% dose in Eimeria tenella-infected chicks.
Achieved 0% mortality, 86% weight gain relative to UUC, and ADI of 1.6 at 0.025% dose in Eimeria tenella-infected chicks.
Achieved 0% mortality, 71% weight gain relative to UUC, and ADI of 0.7 at 0.1% dose in Eimeria necatrix-infected chicks.
Achieved 5% mortality, 60% weight gain relative to UUC, and ADI of 1.9 at 0.05% dose in Eimeria necatrix-infected chicks.
Achieved 50% mortality, 39% weight gain relative to UUC, and ADI of 3.4 at 0.025% dose in Eimeria necatrix-infected chicks.
Achieved 0% mortality, 86% weight gain relative to UUC, and ADI of 0.3 at 0.1% dose in Eimeria acervulina-infected chicks.
Achieved 0% mortality, 101% weight gain relative to UUC, and ADI of 0.3 at 0.05% dose in Eimeria acervulina-infected chicks.
Achieved 0% mortality, 92% weight gain relative to UUC, and ADI of 1.6 at 0.025% dose in Eimeria acervulina-infected chicks.
Achieved 0% mortality, 83% weight gain relative to UUC, and ADI of 0.5 at 0.1% dose in Eimeria maxima-infected chicks.
Achieved 0% mortality, 84% weight gain relative to UUC, and ADI of 0.2 at 0.05% dose in Eimeria maxima-infected chicks.
Achieved 0% mortality, 84% weight gain relative to UUC, and ADI of 0.4 at 0.025% dose in Eimeria maxima-infected chicks.
Achieved 0% mortality, 80% weight gain relative to UUC, and no detectable lesions at 0.1% dose in Eimeria brunetti-infected chicks.
Achieved 0% mortality, 92% weight gain relative to UUC, and no detectable lesions at 0.05% dose in Eimeria brunetti-infected chicks.
Achieved 0% mortality, 89% weight gain relative to UUC, and no detectable lesions at 0.025% dose in Eimeria brunetti-infected chicks.
Achieved 0% mortality, 86% weight gain relative to UUC, and ADI of 0.0 at 0.1% dose in Eimeria mivati-infected chicks.
Achieved 0% mortality, 101% weight gain relative to UUC, and ADI of 0.0 at 0.05% dose in Eimeria mivati-infected chicks.
Achieved 0% mortality, 102% weight gain relative to UUC, and ADI of 0.4 at 0.025% dose in Eimeria mivati-infected chicks.
Animal Model: Peterson Cross (1 day old, grouped by weight and sex, 2 weeks old at test initiation)
Dosage: 0.05%
Administration: p.o.; daily; 6 days
Result: Achieved 0% mortality, 90% weight gain relative to UUC, and ADI of 0.3 in chicks with mixed Eimeria infections.
Animal Model: Broad Breasted White (1 day old, grouped by weight and sex, 2 weeks old at test initiation)
Dosage: 0.05%
Administration: 0.0125%; 0.025%; 0.05%
Result: Achieved 0% mortality, 94% weight gain relative to UUC, and ADI of 0.1 at 0.05% dose in Eimeria gallopavonis-infected turkey poults.
Achieved 0% mortality, 101% weight gain relative to UUC, and ADI of 0.0 at 0.025% dose in Eimeria gallopavonis-infected turkey poults.
Achieved 0% mortality, 89% weight gain relative to UUC, and ADI of 0.1 at 0.0125% dose in Eimeria gallopavonis-infected turkey poults.
Achieved 0% mortality, 77% weight gain relative to UUC, and ADI of 0.0 at 0.05% dose in Eimeria meleagrimitis-infected turkey poults.
Achieved 0% mortality, 78% weight gain relative to UUC, and ADI of 0.5 at 0.025% dose in Eimeria meleagrimitis-infected turkey poults.
Achieved 0% mortality, 79% weight gain relative to UUC, and ADI of 0.8 at 0.0125% dose in Eimeria meleagrimitis-infected turkey poults.
Achieved 0% mortality, 89% weight gain relative to UUC, and ADI of 0.0 at 0.05% dose in Eimeria adenoeides-infected turkey poults.
Achieved 0% mortality, 98% weight gain relative to UUC, and ADI of 0.0 at 0.025% dose in Eimeria adenoeides-infected turkey poults.
Achieved 0% mortality, 100% weight gain relative to UUC, and ADI of 0.1 at 0.0125% dose in Eimeria adenoeides-infected turkey poults.
性状 固体
颜色 White to off-white

化学信息

分子量 332.31
分子式 C12H13N4NaO4S
CAS No. 1037-50-9
别名 Sulphadimethoxine sodium

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (30.09 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.02 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 250 mg/mL (752.31 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0092 mL15.0462 mL30.0924 mL75.2310 mL
5 mM0.6018 mL3.0092 mL6.0185 mL15.0462 mL
10 mM0.3009 mL1.5046 mL3.0092 mL7.5231 mL
15 mM0.2006 mL1.0031 mL2.0062 mL5.0154 mL
20 mM0.1505 mL0.7523 mL1.5046 mL3.7615 mL
25 mM0.1204 mL0.6018 mL1.2037 mL3.0092 mL
30 mM0.1003 mL0.5015 mL1.0031 mL2.5077 mL
40 mM0.0752 mL0.3762 mL0.7523 mL1.8808 mL
50 mM0.0602 mL0.3009 mL0.6018 mL1.5046 mL
60 mM0.0502 mL0.2508 mL0.5015 mL1.2538 mL
80 mM0.0376 mL0.1881 mL0.3762 mL0.9404 mL
100 mM0.0301 mL0.1505 mL0.3009 mL0.7523 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础